基于发病年龄的成人重症肌无力临床与治疗特征
这项西班牙多中心观察性横断面研究纳入939例发病年龄>18岁的重症肌无力患者,按发病年龄分为早发(<50岁)、晚发(≥50且<65岁)和极晚发(≥65岁)三组,比较人口学、免疫学、临床及治疗特征。结果显示极晚发组占比45.2%,男性更多,抗AChR抗体阳性率更高且胸腺瘤更少,虽起病时更易出现威胁生命事件,但所需药物更少且难治性比例更低。
要点
- 极晚发组(≥65岁)占45.2%,男性更多,抗AChR抗体阳性率更高且胸腺瘤更少。
- 晚发和极晚发组起病时及最大加重时眼肌型比例更高。
- 极晚发组起病时更易出现威胁生命事件,但所需药物更少且难治性比例更低。
核心结论
- 重症肌无力患者主要为≥65岁、抗AChR抗体阳性且无胸腺瘤者。
- 极晚发患者虽起病时可能出现威胁生命事件,但经恰当诊治后以较少免疫抑制剂即可获得良好结局。
研究设计与样本
- 基于西班牙神经科医生驱动的神经肌肉疾病注册登记(NMD-ES)的观察性横断面多中心研究。
- 纳入939例发病年龄>18岁且2000至2016年间发病的重症肌无力患者,来自15家医院。
- 按发病年龄分为早发(<50岁)、晚发(≥50且<65岁)和极晚发(≥65岁)三组,平均随访9.1年(SD 4.3)。
主要发现
- 早发组288例(30.7%),晚发组227例(24.2%),极晚发组424例(45.2%)。
- 晚发和极晚发组男性比例更高(p < 0.0001)。
- 极晚发组抗AChR抗体阳性率更高(p < 0.0001)且胸腺瘤更少(p < 0.0001)。
- 晚发和极晚发组眼肌型重症肌无力在起病时(p < 0.0001)和最大加重时(p = 0.001)更常见。
- 极晚发组起病时威胁生命事件(MGFA IVB和V)更多(p = 0.002),但所需药物更少(p < 0.0001)且难治性比例更低(p < 0.0001)。
临床怎么用
- 对≥65岁发病的重症肌无力患者应检测抗AChR抗体并评估胸腺瘤。
- 极晚发患者起病时需警惕威胁生命事件,但规范诊治后免疫抑制剂需求较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the characteristics of patients with very-late-onset myasthenia gravis (MG). METHODS: This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular Diseases (NMD-ES). All patients were >18 years of age at onset of MG and onset occurred between 2000 and 2016 in all cases. Patients were classified into 3 age subgroups: early-onset MG (age at onset <50 years), late-onset MG (onset ≥50 and <65 years), and very-late-onset MG (onset ≥65 years). Demographic, immunologic, clinical, and therapeutic data were reviewed. RESULTS: A total of 939 patients from 15 hospitals were included: 288 (30.7%) had early-onset MG, 227 (24.2%) late-onset MG, and 424 (45.2%) very-late-onset MG. The mean follow-up was 9.1 years (SD 4.3). Patients with late onset and very late onset were more frequently men (p < 0.0001). Compared to the early-onset and late-onset groups, in the very-late-onset group, the presence of anti-acetylcholine receptor (anti-AChR) antibodies (p < 0.0001) was higher and fewer patients had thymoma (p < 0.0001). Late-onset MG and very-late-onset MG groups more frequently had ocular MG, both at onset (<0.0001) and at maximal worsening (p = 0.001). Although the very-late-onset group presented more life-threatening events (Myasthenia Gravis Foundation of America IVB and V) at onset (p = 0.002), they required fewer drugs (p < 0.0001) and were less frequently drug-refractory (p < 0.0001). CONCLUSIONS: Patients with MG are primarily ≥65 years of age with anti-AChR antibodies and no thymoma. Although patients with very-late-onset MG may present life-threatening events at onset, they achieve a good outcome with fewer immunosuppressants when diagnosed and treated properly.
引用
- Cortés-Vicente E, Álvarez-Velasco R, Segovia S, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020. PMID: 32071167. doi:10.1212/WNL.0000000000008903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。